Close
CDMO Safety Testing 2026
Novotech

Sandoz announces launch of piperacillin and tazobactam for injection, a generic version of Zosyn

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

- Advertisement -

Sandoz anounced the launch of piperacillin and tazobactam for injection, a generic equivalent of Zosyn®, in the US. Piperacillin and tazobactam for injection is an antibacterial treatment indicated for use in adults with certain types of moderate to severe infections caused by piperacillin-resistant, piperacillin/tazobactam susceptible, ß-lactamase producing strains. Don DeGolyer, President of Sandoz Inc said, Sandoz has a long history of global leadership in developing high-quality, affordable anti-infective medicines. The US launch of piperacillin and tazobactam for injection, or generic Zosyn®, further strengthens our portfolio in this key field as well as our commitment to differentiated products, including injectables

According to IMS Health, branded and generic versions of piperacillin and tazobactam for injection had US sales of approximately USD 797 million for the 12 months ending in August 2010. Sandoz is marketing piperacillin and tazobactam for injection in 2.25 g, 3.375 g and 4.5 g vials, the same standard vial strengths marketed for Zosyn®.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Latest stories

Related stories

QIAGEN and NVIDIA Join Forces to Advance AI-Driven Drug Discovery

QIAGEN's Digital Insights bioinformatics division is set to integrate...

AstraZeneca’s Baxfendy Wins FDA Approval for Uncontrolled Hypertension

AstraZeneca's hypertension drug baxdrostat, branded as Baxfendy, has received...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »